Story perspectives

EMA Approves Acoziborole: Game-Changer for Sleeping Sickness

2/27/2026

Summary

Story summary

The European Medicines Agency (EMA) approved acoziborole, a new sleeping sickness treatment.
The decision enables Congo, which has the highest sleeping sickness cases, to access the drug.
Acoziborole requires just three pills as a one-time dose, simplifying treatment.
A study shows over 95% cure after 18 months.
Sanofi will donate doses to the World Health Organization to ensure free patient access, supporting the 2030 goal to stop sleeping sickness.

1 of 1

Story summary

The European Medicines Agency (EMA) approved acoziborole, a new sleeping sickness treatment.
The decision enables Congo, which has the highest sleeping sickness cases, to access the drug.
Acoziborole requires just three pills as a one-time dose, simplifying treatment.
A study shows over 95% cure after 18 months.
Sanofi will donate doses to the World Health Organization to ensure free patient access, supporting the 2030 goal to stop sleeping sickness.